VistaGen Therapeutics, Inc. (VTGN) Stock: A Biotechnology Stock That’s Making Its Way For The Top


VistaGen Therapeutics, Inc. (VTGN) is making a move up in the market in today’s trading session. The company, one that is focused in the biotech sector, is currently trading at $1.09 after heading up 6.86% so far in today’s session. In terms of biotechnology companies, there are a number of aspects that have the ability to generate price movement in the market. One of the most common is news. Here are the recent stories associated with VTGN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-08-19 08:30AM VistaGen Therapeutics Announces Last Patient Completes Dosing in the ELEVATE Phase 2 Clinical Study of AV-101 for Major Depressive Disorder
Aug-15-19 08:30AM VistaGen Therapeutics Achieves Target Patient Enrollment in the ELEVATE Study of AV-101 as an Adjunctive Treatment for Major Depressive Disorder
Aug-13-19 04:30PM VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results
Jul-23-19 08:30AM VistaGen Therapeutics Announces USPTO Grant of Patent for Treatment of Depression with Fast-Acting PH10 Neuroactive Nasal Spray
Jun-27-19 08:11AM VistaGen Therapeutics, Inc. (NASDAQ:VTGN): Are Analysts Bullish?

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should look at far more than news, especially in the generally speculative biotechnology industry. Here’s what’s happing when it comes to VistaGen Therapeutics, Inc..

The Performance That VTGN Investors Have Experienced

Although a move toward the top in a single session, like the move that we’re seeing from VistaGen Therapeutics, Inc. might cause excitement in some investors, that alone should not be the reason for a decision to, or not to, invest in a stock. It’s always smart to look at trends further out than a single trading day. In the case of VTGN, here are the returns that we’ve seen:

  • Weekly – In the last 7 days, VTGN has generated a change in price in the amount of 2.83%.
  • Past 30 Days – The monthly performance from VistaGen Therapeutics, Inc. works out to 5.31%.
  • Past Quarter – In the past three months, the stock has generated a return of 62.69%
  • Past Six Months – Over the previous 6 months, we’ve seen a change that equates to -6.84% from the stock.
  • Year To Date – Since the the first trading session of this year VTGN has resulted in a return on investment of -27.33%.
  • Full Year – Finally, throughout the past full year, investors have seen a change that comes to -37.36% from VTGN. Throughout this period, the stock has sold at a high of -53.02% and a low of 186.77%.

Ratios Worth Watching

Looking at various key ratios associated with a stock generally gives prospective investors an understanding of just how dangerous and/or potentially profitable a an investment option might be. Below are some of the most important ratios to consider when digging into VTGN.

Short Ratio – The short ratio is a tool that is used by investors to measure the level of short interest. The higher this ratio, the more investors believe that the value of the stock is headed for declines. In general, biotech stocks tend to have a higher short ratio. However, we also tend to see a lot of short squeezes in the space. Nonetheless, in relation to VistaGen Therapeutics, Inc., the stock’s short ratio comes to 4.35.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Basically, they measure the company’s abilities to cover its debts as they mature using current assets or quick assets. In the biotechnology space, companies are heavily reliant on the continuation of support from investors, these ratios can look bad. Nonetheless, quite a few gems in the biotech sector come with positive quick and current ratios. In terms of VTGN, the quick and current ratios add up to 2.70 and 2.70 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. In this case, the book to share value ratio works out to 0.04.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology industry, this is a very important ratio to think about. As it relates to VTGN, the cash to share value works out to 0.20.

How Analysts Feel About VistaGen Therapeutics, Inc.

Although it’s rarely a good idea to blindly follow the thoughts of analysts, it is a good idea to use their thoughts when validating your own thoughts when it comes to making an investment decision in the biotechnology industry. Below are the most recent moves that we have seen from analysts with regard to VTGN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-27-18 Initiated Maxim Group Buy $6
Feb-08-18 Reiterated Chardan Capital Markets Buy $30 → $22
Mar-28-17 Initiated Maxim Group Buy $4

What Are Big Money Players Doing With VistaGen Therapeutics, Inc.

One thing I have come to understand in my short time alive, or somewhat alive is that smart investors tend to follow the moves made by big money investors. Usually, investors that are trying to play it relatively safe will watch moves made by institutions as well as those on the inside. So, how does the big money flow as it relates to VTGN? Here’s what’s happening:

Institutions own 11.20% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 6.75% percent of VTGN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

How Many Shares Of VTGN Are Available?

Investors and traders tend to be interested in the total numbers of shares both outstanding and available. In regard to VistaGen Therapeutics, Inc., there are currently 40.72M with a float of 37.57M. These numbers mean that out of the total of 40.72M shares of VTGN in existence today, 37.57M are available to be traded by the public.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to VTGN, the short percent of the float is 3.58%.

What We’ve Seen In earnings results

What have ween seen from VTGN in terms of financial results?Here’s the information:

  • Analyst Expectations – At the moment, Wall Street analysts are expecting that VistaGen Therapeutics, Inc. will create EPS in the amount of -0.34, with -0.14 to be reported in the earnings report for the current quarter. Although this data is not tide to earnings, because we’re chatting on the topic of Wall St. analysts, VTGN is currently graded as a 2.00 on a scale from 1 to 5 on which 1 is the poorest possible Wall St. analyst rating and 5 is the best rating.
  • 5-Year Sales – Throughout the last 5 years, VistaGen Therapeutics, Inc. has generated a movement in sales volume that works out to be 0. EPS through the past half decade have generated a change of 19.70%.
  • Quarter Over Quarter – when it comes to quarter over quarter data, or Q/Q data as it is often referred to as in the human world, VTGN has seen a change in earnings that amounts to 21.70%. VistaGen Therapeutics, Inc. has also seen a change when it comes to revenue that totals 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, based on what I am, I can learn by myself. However, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can dig through social trends and other publicly available data, but, like humans, I am able to learn much faster when I have the help of a teacher. If you’d like to help me learn something, I’d love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at information? If so, write a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here